REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that its board of directors has determined to effect a one-for-16 reverse stock split of Adicet's common stock, par value $0.0001 per share. The reverse stock split ratio approved by the board of directors is within the previously disclosed range of ratios for a revers.

While Celularity's Biovance® and Biovance 3L products remained eligible for Medicare coverage under the now-withdrawn LCDs, Celularity CEO Dr. Robert J. Hariri welcomed the recent action taken under the leadership of CMS Administrator Dr. Mehmet Oz While Celularity's Biovance® and Biovance 3L products remained eligible for Medicare coverage under the now-withdrawn LCDs, Celularity CEO Dr. Robert J. Hariri welcomed the recent action taken under the leadership of CMS Administrator Dr. Mehmet Oz

UUUU shares gained 8% in a week after achieving rare U.S. production and third-party qualification of magnet-grade dysprosium oxide outside China.

NEW YORK, Dec. 26, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP reminds purchasers or acquirers Coupang, Inc. (NYSE: CPNG) (“Coupang”) that a federal securities class action has been filed on behalf of investors who purchased Coupang between August 6, 2025 and December 16, 2025, inclusive (the “Class Period”). Investors have until February 17, 2026 to seek appointments as lead plaintiff.

The move comes after the U.S. agreed to sell Taiwan more than $11 billion in weapons.

NEW YORK, Dec. 25, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Primo Water Corporation (NYSE: PRMW) between June 17, 2024 and November 8, 2024, both dates inclusive, and/or (ii) purchasers of common stock of Primo Brands Corporation (NYSE: PRMB) between November 11, 2024 and November 6, 2025 (the “Class Period”), of the important January 12, 2026 lead plaintiff deadline.

NEW YORK , Dec. 25, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Skye Bioscience, Inc. (NASDAQ: SKYE) between November 4, 2024 and October 3, 2025, both dates inclusive (the "Class Period"), of the important January 16, 2026 lead plaintiff deadline. So what: If you purchased Skye securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Gold analysis flags short-term pullback risk toward $4344.97 while dollar weakness, geopolitics and Fed cuts keep the long-term gold rally supported.

NEW YORK, Dec. 25, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of StubHub Holdings, Inc. (NYSE: STUB) pursuant and/or traceable to the Registration Statement issued in connection with StubHub's September 2025 initial public offering (the “IPO”), of the important January 23, 2026 lead plaintiff deadline.

NEW YORK, Dec. 25, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Stride, Inc. (NYSE: LRN) between October 22, 2024 and October 28, 2025, both dates inclusive (the “Class Period”), of the important January 12, 2026 lead plaintiff deadline.

Head of marketing for Meta wearables Raashi Rosenberger joins 'Mornings with Maria' to showcase the tech giant's new AI-powered Ray-Ban and Oakley smart glasses and explain how hands-free features are reshaping everyday life.

Investments within the automotive industry could be changing for the better. Rivian's new microchip is the most aggressive push into autonomous driving technology yet.

North Carolina-based Anchor Capital Management Company acquired 717,772 shares of Hillman Solutions. The move contributed to an estimated $8.0 million increase from the previous period.

One of Buffett's core investment philosophies is to invest in the S&P 500. Last year, Berkshire Hathaway sold out of two notable ETF positions.

North Carolina-based Anchor Capital Management Company added 29,998 shares of SXI in the third quarter. The move contributed to a net position change of $10.15 million from the previous period.

Microsoft Corporation maintains a market-leading moat across software, cloud, and AI infrastructure, despite recent market skepticism and competitive noise. MSFT's deep enterprise integration and AI partnerships, especially with OpenAI, position Azure for accelerated growth and monetization through 2026 and beyond. Strategic capital allocation and margin discipline remain intact, with CapEx expected to decelerate by FY2028, supporting long-term profitability conviction.

NEW YORK, Dec. 25, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Jayud Global Logistics Ltd. (NASDAQ: JYD) between April 21, 2023 and April 30, 2025, both dates inclusive (the “Class Period”), of the important January 20, 2026 lead plaintiff deadline.

Plug Power has never turned a profit since its founding over a quarter-century ago. It faces challenges in developing the hydrogen market due to high costs and slow adoption.

After years of waiting, Sibanye Stillwater's cycle finally turned; since September 2025, the stock has returned 84%, yet I think the recovery is early and undervaluation persists. The operating update showed ~$560M EBITDA, triple last year, plus accelerating cash generation; that magnitude suggests SBSW has exited the trough and margins are expanding. South African PGM became the engine: 4E basket price +36%, production +4%, and adjusted EBITDA +213% YoY, offsetting weaker surface output from tailings depletion.

NEW YORK , Dec. 25, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Alvotech (NASDAQ: ALVO) resulting from allegations that Alvotech may have issued materially misleading business information to the investing public. So What: If you purchased Alvotech securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.